Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer. Rugo HS. N Engl J Med 2026;394:918-920.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rugo HS. Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer. N Engl J Med 2026;394:918-920.
PMID: 41740036